Trial reportRMD open2025
Serum biochemical marker of synovial tissue turnover, C1M, predicts radiological progression in early rheumatoid arthritis.
Trial report in RMD open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate whether serum C1M and C2M, biochemical markers of synovial and cartilage tissue destruction, were associated with progression of joint damage in patients with early arthritis.
methods813 early arthritis patients (<6 months of symptoms, 82% with rheumatoid arthritis, 18% undifferentiated arthritis) from the prospective ESPOIR study were followed for 5 years. Radiographic progression was assessed using the van der Heijde Sharp score, and progression was defined as an increase of 1 or 5 unit(s) between baseline and 1 year or 5 years. Associations between baseline C1M and C2M and progression were assessed by logistic regression.
resultsIncreased baseline continuous serum C1M levels were associated with the risk of progression at 1 year, after adjustment for age, gender and body mass index (BMI). Patients with levels in the highest quartile of C1M had an OR (95% CI) of total joint damage progression of 2.75 (1.70-4.45) compared with patients in the lowest quartile. When disease activity score 28, C reactive protein and anticyclic citrullinated peptide 2 antibodies positivity were included in the model, high C1M remained significantly associated with progression with an OR (95% CI) of 2.12 (1.06-4.23). At 5 years, C1M was significantly associated with the risk of total joint damage progression after adjustment for age, gender and BMI. There was no significant association of C2M with progression at 1 year or 5 years.
conclusionsHigh baseline serum C1M, but not C2M, is associated with increased radiographic progression in early arthritis, independently of classical risk factors. C1M, in conjunction with other risk factors, may help identify patients at higher risk of joint damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.